| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received November 1, 2007
Accepted on March 24, 2008
CLINICAL RESEARCH |
,
,
1
*Department of Biostatistics,
Division of Nephrology,
Division of Nephrology, Puget Sound Veterans’ Affairs Medical Center, and
Division of Nephrology, Harborview Medical Center, University of Washington, Seattle, Washington
1 To whom correspondence should be addressed. E-mail: brk{at}u.washington.edu.
| Abstract |
|---|
Parenteral vitamin D is associated with improved survival among long-term hemodialysis patients. Among nondialyzed patients with chronic kidney disease (CKD), oral activated vitamin D reduces parathyroid hormone levels, but the impact on clinical outcomes is unknown. We evaluated associations of oral calcitriol use with mortality and dialysis dependence in 1418 nondialysis patients with CKD and hyperparathyroidism in the Veterans Affairs Consumer Health Information and Performance Sets database. Incident calcitriol users and nonusers were selected on the basis of stages 3 to 4 CKD, hyperparathyroidism, and the absence of hypercalcemia before calcitriol use and then were matched by age and estimated kidney function. During a median follow-up of 1.9 yr, 408 (29%) patients died and 217 (16%) initiated long-term dialysis. After adjustment for demographics; comorbidities; estimated kidney function; medications; and baseline levels of parathyroid hormone, calcium, and phosphorous, oral calcitriol use was associated with a 26% lower risk for death (95% confidence interval 5 to 42% lower; P = 0.016) and a 20% lower risk for death or dialysis (95% confidence interval 1 to 35% lower; P = 0.038). The association of calcitriol with improved survival was not statistically different across baseline parathyroid hormone levels. Calcitriol use was associated with a greater risk for hypercalcemia. In conclusion, oral calcitriol use is associated with lower mortality in nondialysis patients with CKD.
Related Articles
This article has been cited by other articles:
![]() |
C.-C. Szeto and P. K.-T. Li The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism NDT Plus, June 1, 2009; 2(3): 205 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Negri Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD Nephrol. Dial. Transplant., February 1, 2009; 24(2): 341 - 344. [Full Text] [PDF] |
||||
![]() |
T. B. Drueke and E. Ritz Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wolf Active Vitamin D and Survival J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1442 - 1443. [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673